These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 19074476)

  • 1. Estrogen attenuates left ventricular and cardiomyocyte hypertrophy by an estrogen receptor-dependent pathway that increases calcineurin degradation.
    Donaldson C; Eder S; Baker C; Aronovitz MJ; Weiss AD; Hall-Porter M; Wang F; Ackerman A; Karas RH; Molkentin JD; Patten RD
    Circ Res; 2009 Jan; 104(2):265-75, 11p following 275. PubMed ID: 19074476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stachydrine hydrochloride suppresses phenylephrine-induced pathological cardiac hypertrophy by inhibiting the calcineurin/nuclear factor of activated T-cell signalling pathway.
    Zheng J; Tian J; Wang S; Hu P; Wu Q; Shan X; Zhao P; Zhang C; Guo W; Xu M; Chen H; Lu R
    Eur J Pharmacol; 2020 Sep; 883():173386. PubMed ID: 32712088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Muscle-specific RING finger 1 negatively regulates pathological cardiac hypertrophy through downregulation of calcineurin A.
    Maejima Y; Usui S; Zhai P; Takamura M; Kaneko S; Zablocki D; Yokota M; Isobe M; Sadoshima J
    Circ Heart Fail; 2014 May; 7(3):479-90. PubMed ID: 24526353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of ADAM15 in female mice does not worsen pressure overload cardiomyopathy, independent of ovarian hormones.
    Krishnan V; Atanasova N; Aujla PK; Hupka D; Owen CA; Kassiri Z
    Am J Physiol Heart Circ Physiol; 2024 Aug; 327(2):H409-H416. PubMed ID: 38607341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polydatin attenuates cardiac hypertrophy through modulation of cardiac Ca2+ handling and calcineurin-NFAT signaling pathway.
    Ding W; Dong M; Deng J; Yan D; Liu Y; Xu T; Liu J
    Am J Physiol Heart Circ Physiol; 2014 Sep; 307(5):H792-802. PubMed ID: 25015961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 17 Beta-estradiol differentially affects left ventricular and cardiomyocyte hypertrophy following myocardial infarction and pressure overload.
    Patten RD; Pourati I; Aronovitz MJ; Alsheikh-Ali A; Eder S; Force T; Mendelsohn ME; Karas RH
    J Card Fail; 2008 Apr; 14(3):245-53. PubMed ID: 18381189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A gene therapeutic approach to inhibit calcium and integrin binding protein 1 ameliorates maladaptive remodelling in pressure overload.
    Grund A; Szaroszyk M; Döppner JK; Malek Mohammadi M; Kattih B; Korf-Klingebiel M; Gigina A; Scherr M; Kensah G; Jara-Avaca M; Gruh I; Martin U; Wollert KC; Gohla A; Katus HA; Müller OJ; Bauersachs J; Heineke J
    Cardiovasc Res; 2019 Jan; 115(1):71-82. PubMed ID: 29931050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aspirin Attenuates Angiotensin II-induced Cardiomyocyte Hypertrophy by Inhibiting the Ca(2+)/Calcineurin-NFAT Signaling Pathway.
    Yin Z; Wang X; Zhang L; Zhou H; Wei L; Dong X
    Cardiovasc Ther; 2016 Feb; 34(1):21-9. PubMed ID: 26506219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PICOT attenuates cardiac hypertrophy by disrupting calcineurin-NFAT signaling.
    Jeong D; Kim JM; Cha H; Oh JG; Park J; Yun SH; Ju ES; Jeon ES; Hajjar RJ; Park WJ
    Circ Res; 2008 Mar; 102(6):711-9. PubMed ID: 18258855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Syndecan-4 is essential for development of concentric myocardial hypertrophy via stretch-induced activation of the calcineurin-NFAT pathway.
    Finsen AV; Lunde IG; Sjaastad I; Østli EK; Lyngra M; Jarstadmarken HO; Hasic A; Nygård S; Wilcox-Adelman SA; Goetinck PF; Lyberg T; Skrbic B; Florholmen G; Tønnessen T; Louch WE; Djurovic S; Carlson CR; Christensen G
    PLoS One; 2011; 6(12):e28302. PubMed ID: 22164265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcineurin activity is required for cardiac remodelling in pregnancy.
    Chung E; Yeung F; Leinwand LA
    Cardiovasc Res; 2013 Dec; 100(3):402-10. PubMed ID: 23985902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac anti-remodelling effect of aerobic training is associated with a reduction in the calcineurin/NFAT signalling pathway in heart failure mice.
    Oliveira RS; Ferreira JC; Gomes ER; Paixão NA; Rolim NP; Medeiros A; Guatimosim S; Brum PC
    J Physiol; 2009 Aug; 587(Pt 15):3899-910. PubMed ID: 19505981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic inhibition of calcineurin induces diastolic dysfunction in mice with chronic pressure overload.
    Gelpi RJ; Gao S; Zhai P; Yan L; Hong C; Danridge LM; Ge H; Maejima Y; Donato M; Yokota M; Molkentin JD; Vatner DE; Vatner SF; Sadoshima J
    Am J Physiol Heart Circ Physiol; 2009 Nov; 297(5):H1814-9. PubMed ID: 19717730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased cholinergic activity under conditions of low estrogen leads to adverse cardiac remodeling.
    Teixeira VP; Miranda K; Scalzo S; Rocha-Resende C; Silva MM; Tezini GCSV; Melo MB; Souza-Neto FP; Silva KSC; Jesus ICG; Santos AK; de Oliveira M; Szawka RE; Salgado HC; Prado MAM; Poletini MO; Guatimosim S
    Am J Physiol Cell Physiol; 2021 Apr; 320(4):C602-C612. PubMed ID: 33296286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen receptor beta protects the murine heart against left ventricular hypertrophy.
    Babiker FA; Lips D; Meyer R; Delvaux E; Zandberg P; Janssen B; van Eys G; Grohé C; Doevendans PA
    Arterioscler Thromb Vasc Biol; 2006 Jul; 26(7):1524-30. PubMed ID: 16627800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inorganic arsenic induces sex-dependent pathological hypertrophy in the heart.
    Kabir R; Sinha P; Mishra S; Ebenebe OV; Taube N; Oeing CU; Keceli G; Chen R; Paolocci N; Rule A; Kohr MJ
    Am J Physiol Heart Circ Physiol; 2021 Apr; 320(4):H1321-H1336. PubMed ID: 33481702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triad3A attenuates pathological cardiac hypertrophy involving the augmentation of ubiquitination-mediated degradation of TLR4 and TLR9.
    Lu X; He Y; Tang C; Wang X; Que L; Zhu G; Liu L; Ha T; Chen Q; Li C; Xu Y; Li J; Li Y
    Basic Res Cardiol; 2020 Feb; 115(2):19. PubMed ID: 32008145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy.
    Wilkins BJ; Dai YS; Bueno OF; Parsons SA; Xu J; Plank DM; Jones F; Kimball TR; Molkentin JD
    Circ Res; 2004 Jan; 94(1):110-8. PubMed ID: 14656927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiomyocyte dimethylarginine dimethylaminohydrolase-1 (DDAH1) plays an important role in attenuating ventricular hypertrophy and dysfunction.
    Xu X; Zhang P; Kwak D; Fassett J; Yue W; Atzler D; Hu X; Liu X; Wang H; Lu Z; Guo H; Schwedhelm E; Böger RH; Chen P; Chen Y
    Basic Res Cardiol; 2017 Aug; 112(5):55. PubMed ID: 28819685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased KCNE2 Expression Participates in the Development of Cardiac Hypertrophy by Regulation of Calcineurin-NFAT (Nuclear Factor of Activated T Cells) and Mitogen-Activated Protein Kinase Pathways.
    Liu W; Deng J; Ding W; Wang G; Shen Y; Zheng J; Zhang X; Luo Y; Lv C; Wang Y; Chen L; Yan D; Boudreau RL; Song LS; Liu J
    Circ Heart Fail; 2017 Jun; 10(6):. PubMed ID: 28611128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.